Appili Therapeutics Common Shares to Begin Trading on June 25, 2019 on the TSXV Under the Stock Symbol “APLI”
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES NEWS WIRE SERVICES
HALIFAX, Nova Scotia, June 24, 2019 – Biopharmaceutical company Appili Therapeutics Inc. ("Appili" or the "Company") is pleased to announce that the TSX Venture Exchange (the “TSXV”) has accepted the Company’s application to list its Class A common shares (the “Common Shares”) on the TSXV. The Common Shares will begin trading at the opening of markets tomorrow, June 25, 2019, under the symbol “APLI."
Appili is a biopharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease. Since incorporation in 2015, the Company has focused on building and advancing a diverse portfolio of anti-infective programs, while developing strategic partnerships and establishing a team of world-class drug development professionals and a board of directors comprised of experienced pharmaceutical industry executives. Cumulatively, this has allowed the Company to advance solutions for patients and public health where significant challenges in infectious disease exist.
“Appili has a clear and unwavering mission: to tackle the growing number of threats in the infectious disease landscape. Listing our shares on the TSXV is an important milestone in our maturation in support of this mission,” said Kevin Sullivan, the Chief Executive Officer of Appili. “We’ve already built a sturdy financial foundation; recruited a strong base of investors; assembled a steadfast, smart, and diverse leadership team; and created a pipeline of three attractive assets with near-term milestones. Taking the Company public is expected to enable access to additional capital and resources, thus expanding our potential to address more unmet needs – and ultimately create more value for shareholders and solutions for patients.”
Mr. Sullivan continued, “According to both the World Health Organization and the U.S. Centers for Disease Control and Prevention, there remains an increasing need for innovations to combat the mounting threats of infectious diseases. To date we have made strong efforts to be efficient with the capital entrusted to us by our shareholders. We have combined the $15.4M in equity raised with over $19M in non-dilutive funding to advance our programs. Our public listing marks an important inflection point in our ability to deepen our reach into this market and demonstrate that it is possible to invest in a compelling and attractive social mission and business opportunity in parallel.”
No securities regulatory authority has either approved or disapproved the contents of this news release. The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws. Accordingly, the Common Shares may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities of Appili in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Appili Therapeutics
Appili was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats to global public health. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, being developed to mitigate the risks of a very serious biological weapons threat. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, which are a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs. ATI-1501 employs Appili’s proprietary, taste-masked, oral-suspension technology with the marketed antibiotic metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments, and government agencies.
Certain information in this press release contains forward-looking statements. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. Such statements relate to estimates, plans, expectations, opinions, forecasts, targets, guidance and include, but are not limited to the timing of commencement of trading of the Common Shares on the TSXV, the future operations and plans of development of Appili and other statements that are not historical facts. This information is based on current expectations and assumptions that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading “Risk Factors” in the final prospectus of the Company dated June 12, 2019, a copy of which is available under the Company’s profile on SEDAR at www.sedar.com. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by applicable securities laws.
Neither the TSXV, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Media Relations Contacts:
Andrea Cohen, Sam Brown Inc.
Investor Relations Contact:
Kimberly Stephens, CFO
i. World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014
ii. U.S. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013 (AR Threats Report).